BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Proposed R&D tax incentive could hurt Australia’s small firms
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Proposed R&D tax incentive could hurt Australia’s small firms
Oct. 3, 2016
By
Tamra Sami
No Comments
PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country.
BioWorld